OssDsign AB (publ) (OSSD.ST)
SEK 10.08
(0.4%)
SEK 10.08
(0.4%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 105.25 Million SEK | 15.17% |
| 2022 | 91.39 Million SEK | 12.46% |
| 2021 | 81.26 Million SEK | -39.62% |
| 2020 | 134.58 Million SEK | 648.01% |
| 2019 | 17.99 Million SEK | -34.88% |
| 2018 | 27.62 Million SEK | 39.8% |
| 2017 | 19.76 Million SEK | 82.07% |
| 2016 | 10.85 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 89.5 Million SEK | -14.97% |
| 2024 Q2 | 81.6 Million SEK | -8.82% |
| 2023 Q4 | 105.25 Million SEK | 13.41% |
| 2023 Q2 | 82.7 Million SEK | -3.02% |
| 2023 FY | 105.25 Million SEK | 15.17% |
| 2023 Q1 | 85.28 Million SEK | -6.69% |
| 2023 Q3 | 92.81 Million SEK | 12.22% |
| 2022 Q4 | 91.39 Million SEK | 9.76% |
| 2022 Q2 | 84.27 Million SEK | 4.73% |
| 2022 FY | 91.39 Million SEK | 12.46% |
| 2022 Q1 | 80.46 Million SEK | -0.98% |
| 2022 Q3 | 83.26 Million SEK | -1.19% |
| 2021 Q3 | 100.17 Million SEK | -31.79% |
| 2021 FY | 81.26 Million SEK | -39.62% |
| 2021 Q4 | 81.26 Million SEK | -18.88% |
| 2021 Q2 | 146.86 Million SEK | 9.71% |
| 2021 Q1 | 133.86 Million SEK | -0.53% |
| 2020 Q2 | 26.27 Million SEK | 69.34% |
| 2020 FY | 134.58 Million SEK | 648.01% |
| 2020 Q3 | 32.59 Million SEK | 24.07% |
| 2020 Q1 | 15.51 Million SEK | -13.77% |
| 2020 Q4 | 134.58 Million SEK | 312.89% |
| 2019 Q3 | 14.99 Million SEK | -14.07% |
| 2019 Q1 | 21.69 Million SEK | -21.48% |
| 2019 FY | 17.99 Million SEK | -34.88% |
| 2019 Q4 | 17.99 Million SEK | 20.02% |
| 2019 Q2 | 17.44 Million SEK | -19.58% |
| 2018 FY | 27.62 Million SEK | 39.8% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q4 | 27.62 Million SEK | 0.0% |
| 2017 FY | 19.76 Million SEK | 82.07% |
| 2016 FY | 10.85 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | -857.056% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 96.064% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 96.064% |
| Arcoma AB | 33.3 Million SEK | -216.04% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | 68.075% |
| BICO Group AB (publ) | 3.26 Billion SEK | 96.776% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | 62.395% |
| CellaVision AB (publ) | 212.32 Million SEK | 50.426% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | -641.403% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -1432.362% |
| C-Rad AB (publ) | 122.4 Million SEK | 14.006% |
| Duearity AB (publ) | 17.53 Million SEK | -500.439% |
| Dignitana AB (publ) | 37.56 Million SEK | -180.185% |
| Episurf Medical AB (publ) | 19.8 Million SEK | -431.601% |
| Getinge AB (publ) | 24.69 Billion SEK | 99.574% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | -410.949% |
| Iconovo AB (publ) | 14.55 Million SEK | -623.222% |
| Integrum AB (publ) | 22.07 Million SEK | -376.862% |
| Luxbright AB (publ) | 7 Million SEK | -1403.646% |
| Mentice AB (publ) | 163.55 Million SEK | 35.644% |
| Paxman AB (publ) | 44.5 Million SEK | -136.485% |
| Promimic AB (publ) | 16.15 Million SEK | -551.504% |
| Qlife Holding AB (publ) | 62.16 Million SEK | -69.308% |
| SciBase Holding AB (publ) | 21.27 Million SEK | -394.675% |
| ScandiDos AB (publ) | 37.18 Million SEK | -183.055% |
| Sectra AB (publ) | 1.64 Billion SEK | 93.587% |
| Sedana Medical AB (publ) | 44.06 Million SEK | -138.884% |
| Senzime AB (publ) | 58.06 Million SEK | -81.274% |
| SpectraCure AB (publ) | 14.97 Million SEK | -602.885% |
| Stille AB | 172.64 Million SEK | 39.031% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 97.13% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | 57.992% |